Autoimmune Encephalitis
New autoimmune encephalitis research, summarized each month in plain language.
2026 so far: From January 2026 to September 2026, early reports highlighted stepping up treatment beyond first-line immunotherapy, along with a stronger push to combine tests to reduce misdiagnosis and to better track relapse and long-term symptoms. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- When first treatments fail. More reports looked at step-up options, but most evidence was still uncontrolled.
- Efgartigimod reports. Signals expanded from single cases to small cohorts and review.
- Life after encephalitis. More work quantified lingering symptoms and caregiver strain beyond disability scores.
- Relapse and recovery risk. More cohorts linked relapse and disability to clinical features and MRI changes.
- Getting the diagnosis right. Multiple studies showed antibody tests and referrals can mislead without context.
New
September 2026
- Efgartigimod reports. Early reports linked efgartigimod to better function, without comparison groups.
- Ofatumumab outcomes. Ofatumumab was linked to better seizures and daily function.
- Relapse and brain shrinkage. About 1 in 4 relapsed within a year; MRI shrinkage linked to disability.
- Multi-test diagnosis. Symptoms, MRI, EEG, spinal fluid, and antibodies were used together.
August 2026
- Second-line treatments. Plasma exchange and targeted immune drugs sometimes helped, but results varied.
- Recovery predictors. Early illness severity and other health problems often shaped recovery.
- Ongoing symptoms. Disability scores improved, but memory and daily-life problems often remained.
- Combined testing. Diagnosis often used antibody tests plus spinal fluid and brain imaging.
July 2026
- Diagnosis confidence. Combining test results helped separate autoimmune encephalitis from similar conditions.
- Relapse risk factors. Some spinal fluid findings and symptoms were linked to relapse.
- Severe illness markers. Routine blood tests at admission were linked to ICU need.
- Patient and caregiver impact. Questionnaires measured symptoms, daily function, and caregiver strain.
June 2026
- Extra immune treatments. Some hard-to-treat cases improved after added immune medicines.
- Added seizure medicine. Some children improved after perampanel, but its role was unclear.
- Rehab after severe illness. One person improved after starting intensive rehab late.
- Early severity and recovery. More severe early illness was linked to worse function later.
May 2026
- Seizures as an early clue. In some rapidly worsening brain syndromes, seizures at first presentation helped raise suspicion for autoimmune encephalitis.
- Conditions that can look similar. Some infections and acute intermittent porphyria were reported to initially resemble autoimmune encephalitis.
- PET when MRI is normal. In small studies, PET scans showed brain inflammation patterns even when MRI results were normal.
- Efgartigimod early reports. Small reports linked efgartigimod with symptom improvement over weeks alongside lower IgG levels, with limited safety data.
April 2026
- Plasma exchange in children. In published reports, most children improved after plasma exchange, a blood-filtering treatment.
- Efgartigimod in anti-LGI1. In a small report, adults with anti-LGI1 autoimmune encephalitis improved within about two weeks after efgartigimod.
- Diagnosis often changes. In one referral-center review, about half of referred patients were ultimately found to have another explanation, including some with positive antibodies.
March 2026
- IVIg plus steroids. In anti-LGI1 encephalitis, IVIg combined with IV steroids was linked to faster improvement than either treatment alone.
- Steroid side effects. Higher IV steroid doses were linked to more side effects than lower doses.
- Ongoing executive function issues. Executive function problems often continued over time, and were reported more often in seronegative cases.
- Sleep breathing problems. Overnight sleep testing often found sleep-related breathing problems that were not always obvious from routine evaluation.
February 2026
- Immune therapy response. Immune treatments often came with symptom improvement, but relapses happened.
- Relapse risk. Relapse occurred in some reports, with possible higher-risk features.
- MRI findings. MRI changes helped in some cases, but results still overlapped.
- Ongoing symptoms. Fatigue, thinking problems, and caregiver strain were often described.
January 2026
- Blood purification. Linked to better improvement, but also more side effects.
- One-year relapse. Pooled data linked blood purification to more relapse at 1 year.
- Antibody test details. Results varied by test design and blood vs spinal fluid.
Get the monthly update by email
Subscribe here to receive an email when a new monthly autoimmune encephalitis update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).